MA38816A - Sulfamidase modifiée et sa production - Google Patents
Sulfamidase modifiée et sa productionInfo
- Publication number
- MA38816A MA38816A MA038816A MA38816A MA38816A MA 38816 A MA38816 A MA 38816A MA 038816 A MA038816 A MA 038816A MA 38816 A MA38816 A MA 38816A MA 38816 A MA38816 A MA 38816A
- Authority
- MA
- Morocco
- Prior art keywords
- sulfamidase
- modified
- modified sulfamidase
- production
- mammal
- Prior art date
Links
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 title abstract 8
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 title abstract 8
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
- C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
- C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La présente invention concerne une sulfamidase modifiée, une composition comprenant une sulfamidase modifiée, ainsi que des procédés de préparation d'une sulfamidase modifiée et l'utilisation thérapeutique d'une telle sulfamidase. En particulier, la présente invention concerne une sulfamidase modifiée ne comprenant pratiquement pas d'épitopes pour des récepteurs de reconnaissance de glycane, permettant ainsi le transport de ladite sulfamidase à travers la barrière hémato-encéphalique d'un mammifère, ladite sulfamidase ayant une activité catalytique dans le cerveau dudit mammifère.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14162996 | 2014-04-01 | ||
| PCT/EP2015/057256 WO2015150490A1 (fr) | 2014-04-01 | 2015-04-01 | Sulfamidase modifiée et son procédé de production |
| EP15713502.1A EP2970413B1 (fr) | 2014-04-01 | 2015-04-01 | Sulfamidase modifiée et sa production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38816A true MA38816A (fr) | 2016-01-20 |
| MA38816B1 MA38816B1 (fr) | 2018-10-31 |
Family
ID=50389999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38816A MA38816B1 (fr) | 2014-04-01 | 2015-04-01 | Sulfamidase modifiée et sa production |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9982243B2 (fr) |
| EP (2) | EP2970413B1 (fr) |
| JP (1) | JP6594896B2 (fr) |
| KR (1) | KR20160138282A (fr) |
| CN (1) | CN106414727A (fr) |
| AU (1) | AU2015239126B2 (fr) |
| BR (1) | BR112016022333A2 (fr) |
| CA (1) | CA2943140A1 (fr) |
| CL (1) | CL2016002469A1 (fr) |
| CY (1) | CY1120697T1 (fr) |
| DK (1) | DK2970413T3 (fr) |
| ES (1) | ES2687262T3 (fr) |
| HK (1) | HK1231510A1 (fr) |
| HR (1) | HRP20181507T1 (fr) |
| HU (1) | HUE039691T2 (fr) |
| IL (1) | IL247978A0 (fr) |
| LT (1) | LT2970413T (fr) |
| MA (1) | MA38816B1 (fr) |
| MX (1) | MX368947B (fr) |
| PH (1) | PH12016501812A1 (fr) |
| PL (1) | PL2970413T3 (fr) |
| PT (1) | PT2970413T (fr) |
| RS (1) | RS57842B1 (fr) |
| RU (1) | RU2708026C2 (fr) |
| SA (1) | SA516371859B1 (fr) |
| SG (1) | SG11201608025QA (fr) |
| SI (1) | SI2970413T1 (fr) |
| SM (1) | SMT201800511T1 (fr) |
| UA (1) | UA120432C2 (fr) |
| WO (1) | WO2015150490A1 (fr) |
| ZA (1) | ZA201606492B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20181507T1 (hr) | 2014-04-01 | 2018-11-16 | Swedish Orphan Biovitrum Ab (Publ) | Modificirana sulfamidaza i njena proizvodnja |
| BR112018006278A2 (pt) * | 2015-10-01 | 2018-10-16 | Swedish Orphan Biovitrum Ab Publ | proteína lisossômica modificada e produção da mesma |
| MX2020002918A (es) | 2017-10-02 | 2020-07-22 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas. |
| WO2019145500A1 (fr) | 2018-01-26 | 2019-08-01 | Swedish Orphan Biovitrum Ab (Publ) | Méthode de traitement |
| WO2020047282A1 (fr) | 2018-08-29 | 2020-03-05 | University Of Copenhagen | Enzymes lysosomales modifiées par glyco-ingénierie basée sur les cellules |
| EP3741867A1 (fr) | 2019-05-24 | 2020-11-25 | Swedish Orphan Biovitrum AB (Publ) | Dosage d'activité de sulfatase |
| AU2021362209B2 (en) | 2020-10-14 | 2026-02-12 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5863782A (en) | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
| JP4503706B2 (ja) | 1996-06-07 | 2010-07-14 | ポニアード ファーマシューティカルズ，インコーポレイティド | グリコシル化が改質されたヒト化抗体 |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
| IL161352A0 (en) | 2001-10-16 | 2004-09-27 | Symbiontics Inc | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| US20040122216A1 (en) | 2002-07-01 | 2004-06-24 | Jacob Nielsen | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
| CA2680189A1 (fr) * | 2007-03-06 | 2008-09-12 | Saint Louis University | Enzyme modifiee et procede de traitement |
| EP2245145B1 (fr) * | 2008-01-18 | 2016-12-14 | BioMarin Pharmaceutical Inc. | Fabrication d'enzymes de sulfatase lysosomales humaines hautement phosphorylées actives et leurs utilisations |
| EP2394667A1 (fr) * | 2010-06-10 | 2011-12-14 | Laboratorios Del Dr. Esteve, S.A. | Vecteurs et séquences pour le traitement de maladies |
| AU2010366066B2 (en) | 2010-12-22 | 2016-01-14 | Fondazione Telethon | Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses |
| WO2012177778A1 (fr) * | 2011-06-20 | 2012-12-27 | Mount Sinai School Of Medicine | Thérapie anti-tnf contre les mucopolysaccharidoses et d'autres maladies lysosomiales |
| WO2014194427A1 (fr) | 2013-06-06 | 2014-12-11 | Angiochem Inc. | Protéines de fusion iduronate-2-sulfatase ciblées |
| US20140377246A1 (en) | 2013-06-19 | 2014-12-25 | Carol Ann Foundation and International Morquio Organization | Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme |
| HRP20181507T1 (hr) | 2014-04-01 | 2018-11-16 | Swedish Orphan Biovitrum Ab (Publ) | Modificirana sulfamidaza i njena proizvodnja |
-
2015
- 2015-04-01 HR HRP20181507TT patent/HRP20181507T1/hr unknown
- 2015-04-01 JP JP2016560417A patent/JP6594896B2/ja not_active Expired - Fee Related
- 2015-04-01 PL PL15713502T patent/PL2970413T3/pl unknown
- 2015-04-01 PT PT15713502T patent/PT2970413T/pt unknown
- 2015-04-01 RU RU2016140844A patent/RU2708026C2/ru not_active IP Right Cessation
- 2015-04-01 ES ES15713502.1T patent/ES2687262T3/es active Active
- 2015-04-01 RS RS20181119A patent/RS57842B1/sr unknown
- 2015-04-01 HK HK17105213.1A patent/HK1231510A1/zh unknown
- 2015-04-01 EP EP15713502.1A patent/EP2970413B1/fr active Active
- 2015-04-01 KR KR1020167030393A patent/KR20160138282A/ko not_active Withdrawn
- 2015-04-01 AU AU2015239126A patent/AU2015239126B2/en not_active Ceased
- 2015-04-01 SI SI201530397T patent/SI2970413T1/sl unknown
- 2015-04-01 UA UAA201610956A patent/UA120432C2/uk unknown
- 2015-04-01 MA MA38816A patent/MA38816B1/fr unknown
- 2015-04-01 EP EP18180516.9A patent/EP3401325A1/fr not_active Withdrawn
- 2015-04-01 CA CA2943140A patent/CA2943140A1/fr not_active Abandoned
- 2015-04-01 MX MX2016012910A patent/MX368947B/es active IP Right Grant
- 2015-04-01 HU HUE15713502A patent/HUE039691T2/hu unknown
- 2015-04-01 BR BR112016022333A patent/BR112016022333A2/pt not_active Application Discontinuation
- 2015-04-01 CN CN201580026957.6A patent/CN106414727A/zh active Pending
- 2015-04-01 LT LTEP15713502.1T patent/LT2970413T/lt unknown
- 2015-04-01 DK DK15713502.1T patent/DK2970413T3/en active
- 2015-04-01 WO PCT/EP2015/057256 patent/WO2015150490A1/fr not_active Ceased
- 2015-04-01 SM SM20180511T patent/SMT201800511T1/it unknown
- 2015-04-01 SG SG11201608025QA patent/SG11201608025QA/en unknown
- 2015-07-22 US US14/806,504 patent/US9982243B2/en active Active
-
2016
- 2016-09-16 PH PH12016501812A patent/PH12016501812A1/en unknown
- 2016-09-19 SA SA516371859A patent/SA516371859B1/ar unknown
- 2016-09-20 ZA ZA2016/06492A patent/ZA201606492B/en unknown
- 2016-09-22 IL IL247978A patent/IL247978A0/en unknown
- 2016-09-30 CL CL2016002469A patent/CL2016002469A1/es unknown
-
2018
- 2018-04-27 US US15/965,597 patent/US20180320152A1/en not_active Abandoned
- 2018-09-24 CY CY181100983T patent/CY1120697T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38816B1 (fr) | Sulfamidase modifiée et sa production | |
| MA43518B1 (fr) | 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase | |
| BR112014026755B8 (pt) | anticorpos contra claudin 18.2 úteis no diagnóstico de câncer | |
| EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| MA40576A (fr) | Anticorps et immunoconjugués anti-her2 | |
| EA201491391A1 (ru) | Терапевтически активные соединения и способы их применения | |
| MX376663B (es) | Anticuerpos anti fc similar a receptor 5 (fcrh5). | |
| EP4374924A3 (fr) | Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate | |
| MA39362A1 (fr) | Compositions stables d'iode non complexé et procédés d'utilisation. | |
| MA44594B1 (fr) | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci | |
| EA201590174A1 (ru) | Иммуноконъюгаты, содержащие анти-cd22 антитела | |
| MA40249A (fr) | Modulateurs des récepteurs d'aryle, et leurs procédés de fabrication et méthodes d'utilisation | |
| EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
| EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
| EA201790407A1 (ru) | Зонды для визуализации белка хантингтина | |
| EA201590171A1 (ru) | ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b | |
| MX380032B (es) | Sintesis de indazoles. | |
| EA201791096A1 (ru) | 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139 | |
| CL2015001279A1 (es) | Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras. | |
| MX2023012628A (es) | Metodos y composiciones para deteccion y diagnostico de enfermedades renales y enfermedades periodontales. | |
| WO2016057683A3 (fr) | Nouveaux anticorps anti-nodaux et méthodes d'utilisation de ceux-ci | |
| EA201692043A1 (ru) | Лекарственная форма иммунодепрессанта | |
| WO2017066712A3 (fr) | Modulateurs de maladie de télomères | |
| EA201691982A1 (ru) | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов | |
| EA201790432A1 (ru) | Зонды для визуализации белка хантингтина |